In May 2025, the Ministry of Health, Labour and Welfare approved a partial change to the manufacturing and sales approval for Autologous Cultured Cartilage JACC, and it was approved for use in treating knee osteoarthritis (however, this is limited to cases where clinical symptoms do not improve with conservative treatments such as exercise therapy and the area of cartilage defect is 2 cm2 or more).
About Knee Osteoarthritis
Knee osteoarthritis is a disease commonly seen among the elderly that causes progressive changes such as wear of cartilage tissue, formation of bone spurs, deformation of the knee joint, and decreased range of motion of the knee joint, as well as pain during exercise.
In severe cases, it is often difficult to walk due to severe pain, and there are concerns about a decline in quality of life (QOL) and activities of daily living.
The use and commercialization of the medicinal products developed by Japan Tissue Engineering Co., Ltd. that are referred to on this website are approved only in Japan. A potential use and commercialization in other regions will be subject to the prior granting of a marketing authorization in the given territory and compliance with applicable laws.